WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$14.27 USD
-0.08 (-0.56%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $14.46 +0.19 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
WVE 14.27 -0.08(-0.56%)
Will WVE be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for WVE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WVE
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
Novavax to Report Q3 Earnings: Here's What to Expect
WVE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know
What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now?
Other News for WVE
Wave Life Sciences price target raised to $22 from $19 at Mizuho
Wave Life Sciences price target raised by $3 at Mizuho, here's why
Wave Life Sciences Advances RNA Medicine Innovations
Insider Sale: President and CEO Paul Bolno Sells 51,234 Shares of WAVE Life Sciences Ltd (WVE)
Positive Outlook for Wave Life Sciences: FDA Support and Strategic Positioning Drive Buy Rating